EP 105: The Year 2023 in Review with Dr Sukh Nijjer
b"In this week's Parallax, Dr Ankur Kalra welcomes back Dr Sukhjinder Nijjer for their much-anticipated annual review of advancements in cardiovascular medicine that defined the year 2023.\\n\\nDr Nijjer, a Consultant Cardiologist in the UK, serves as the President of the Royal Society of Medicine and is an Honorary Senior Clinical Lecturer at Imperial College London.\\n\\nDrs Kalra and Nijjer share their perspectives and experiences, offering valuable insights, practical tips and considerations when interpreting this year\\u2019s most impactful trials:\\n\\n\\u2022 ORBITA-2 (AHA Scientific Sessions): PCI for stable angina\\n\\u2022 FIRE (ESC Congress): Functional versus culprit-only revascularization in elderly patients with myocardial infarction and multivessel disease\\n\\u2022 DAPA-MI (AHA Scientific Sessions): SGLT2i in MI without diabetes or heart failure\\n\\u2022 ILUMIEN IV (ESC Congress): OCT vs angiography-guided PCI\\n\\u2022 OCTOBER (ESC Congress): OCT or Angiography Guidance for PCI in Complex Bifurcation Lesions\\n\\u2022 ARTESIA (ESC Congress): Apixaban for Stroke Prevention in Subclinical Atrial Fibrillation\\n\\u2022 SELECT (AHA Scientific Sessions): Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes\\n\\nWhat are the most impactful cardiovascular trials of 2023? How do Dr Kalra and Dr Nijjer integrate the latest information into their daily practices?"